• InsuraGuest renews InsuraGuest Hospitality Liability coverages contract with Wintergreen resort
• InsuraGuest recently expanded platform integration to about 82 different property management systems connecting with all the big names in the hospitality sector
• InsureThePeople is integrating innovation and technology to deliver to the U.S small business market

InsuraGuest Technologies (TSX.V: ISGI) (OTCQB: ISGIF)  is an insurtech (insurance+technology) company engaged in delivering digital insurance to multiple sectors through its proprietary software platform. The company harnesses the power of technology to deliver insurance digitally across all sectors, empowering clients by offering on-demand insurance products. Insuraguest Technologies recently announced the renewal of its annual contract with Wintergreen Resort in Wintergreen, Virginia, to supply its InsuraGuest Hospitality Liability coverages to the hotel Resort. This specialized guest protection policy is the first line of defense for both the property and the guest (https://ibn.fm/ob2jP). The hotels and rental properties who enroll in the InsuraGuest Hospitality Liability coverages. require their guests to pay a nominal fee at the time of check-in. InsuraGuest then pays out these small claims, shifting the burden from the hotel operator. With no surge in premium prices, there is no impact on the company’s liability policy. With InsuraGuest Hospitality Liability specialized coverages, properties benefit from an additional layer of protection in case a guest encounters an accident, room-damage, theft, or property damage. This prevents the need to make GL claims if an InsuraGuest-covered claim occurs and reduces the hassle, saving time and money for hotel and vacation rental properties. InsuraGuest utilizes a proprietary software platform to deliver these specialized Hospitality Liability coverages. Through its proprietary API, InsuraGuest syncs about 82 different property management systems that allow companies to transfer certain liability exposures to the InsuraGuest carrier (https://ibn.fm/evDmc). InsureThePeople helps small-businesses identify their insurance needs and provides them with on-demand affordable policies. It utilizes InsuraGuest’s proprietary insurtech platform to deliver these customized policies using automation and digital solutions in less than 60 seconds. InsureThePeople hopes to leverage the market of small businesses that make up 99% of America’s 28.7 million businesses. Further, the entrepreneur and freelance markets include 64.8 million people and will reach 90 million by 2028, with an estimated value of $1.8 billion. The last decade has witnessed an investment of $16.5 billion in insurtech, with the emergence of insurtech startups and a sharp increase in fundraising. Insurtech startups are entering the domain of the big players by focusing on meeting the changing consumer demands through increased personalization, greater speed, and accuracy of services through technology. A recent Forbes article (https://ibn.fm/jNL6t) outlines this technological innovation in the digital insurance sector. While InsuraGuest systems already target niche markets like the hospitality sector, the company is geared to extend its services to broader audiences to generate additional revenue streams. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• With Mediscan, the option of having scanning equipment at patient’s location is becoming increasingly viable
• Patent-pending Mediscan software converts ultrasound analog 2D grayscale image into digital 3D HD format
• Software can generate quality 3D medical images of broad variety of organs, including heart, lungs, tendons, skin and nerves

Since its introduction into the world of medicine, the ultrasound has become one of the most efficient, reliable ways to examine the human body in a noninvasive way. And now, this medical mainstay has become even more essential in providing quality care — proprietary technology from HYB Holding (OTC: HYBG) subsidiary Mediscan Inc. can transform traditional 2D images from a portable ultrasound machine into invaluable 3D images to provide even more accurate internal views and, consequently, better diagnosis and health care. “Ultrasounds give an accurate image of body parts in the least amount of time, and even allow the patient to experience real-time results,” reported a recent Mediscan blog. “In fact, [ultrasounds] can produce a high-definition image in less than ten seconds.” That turnaround time is impressive, especially when compared to technologies such as CTs and MRIs, which can take anywhere from 24 hours to an entire week before results are available. The speed of ultrasounds becomes even more critical during emergencies, when the ability to have point-of-care ultrasound (“POCUS”) can save lives. Thanks to Mediscan, the option of having scanning equipment at a patient’s location — whether that is in an ambulance, at an assisted-living facility or even at a patient’s own home — is becoming increasingly viable. Fundamentally, the Mediscan software converts an ultrasound analog 2D grayscale image into a digital 3D HD format. This transformation can take place in traditional ultrasound locations; the Mediscan application integrates with all popular EMR systems. In addition, because the software is designed to pair with portable ultrasound machines, it can be used in less traditional settings. The exclusive software can provide valuable insight to on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms. The process is simple. This patent-pending, cloud-based software application for ultrasound devices is easy to use wherever the internet is available. Once an image has been captured in 2D, it is converted using a cloud-based software application process. The now-3D image can be viewed on a computer monitor, pad or smartphone at the point of service, providing the convenience of point-of-care ultrasound with the image quality of CT or X-ray and the safety of expensive MRI technology. The software can generate quality 3D medical images of a broad variety of organs, including the heart, lungs, tendons, skin and nerves. HYB Holding, through its subsidiary Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• Knightscope, Inc. designs, engineers, builds, deploys, and services autonomous data machines (“ADMs”) also known as security robots
• It currently offers three operational robots in the U.S.: K1 Stationary, K3 Indoors, and K5 Outdoors
• The robots are cheaper for clients per hour compared to human guards and run 24/7
• Knightscope charges between $4 and $11 per hour for its machines on annual contracts, while security companies can charge between $15 and $35 an hour for an unarmed guard and about $85 per hour for an armed guard, according to Knightscope’s CEO
• Investors can purchase shares in Knightscope through its Reg A+ offering
• Since its inception in 2013, Knightscope has generated over $10 million in revenue

Knightscope, a private company that designs, engineers, builds, deploys, and services security robots under the Machine-as-a-Service (“MaaS”) model, aims to woo clients and investors with its cost-effective autonomous data machines (“ADMs”). The California-based company, which was established in 2013, has so far raised $70 million from over 20,000 investors and four major corporations. It is eyeing a possible public listing on NASDAQ under the ticker symbol ‘KSCP’. Knightscope currently offers three operational autonomous machines, namely K1, K3, and K5. K1 is a stationary ADM ideal for indoor and outdoor use at ingress and egress areas, while the latter two are mobile. K3 is designed for indoor usage, while K5 is an outdoor-only ADM. According to its Securities and Exchange Commission (“SEC”) filings, Knightscope earns a revenue ranging between $4,500 and $6,000 per month per ADM. It has so far generated over $10 million in revenue since its inception in 2013 from clients who include hospitals, Fortune 1000 companies, and law enforcement agencies (https://ibn.fm/n7x0i). In a bid to drum up support for its Reg A+ offering, which allows investors to purchase shares in Knightscope today, and to show why clients would be interested in the security robots, William Santana Li, Knightscope’s Chairman and Chief Executive Officer, compared his company’s products to human security guards. According to Li, clients would pay about $85 per hour for an armed guard and between $15 and $35 an hour for an unarmed guard if they chose to go that route. However, in an interview with IPO Edge, Li claimed that his company offers “a technology and a Machine-as-a-Service business model at an effective price of $4 to $11 an hour.” “Most security teams look like a cost center for their clients. They don’t generate revenue, (are) not necessarily brand-enhancing, are usually on the chopping block, and (get) limited budget and resources until something goes wrong. Then they get accused of not doing their job.” Li continued. He termed such a situation as difficult for an organization. He further noted that his company is an attractive option for clients, given that “Folks are either limited on budget or looking genuinely for cost reduction. So, if you’re burning $150 million a year on security guards, you’re going to want to look at it (Knightscope’s services and products)” (https://ibn.fm/QsV10). Li also debunked the conjecture that $4 and $11 an hour would be too low an amount to compel someone to invest in Knightscope. “We sign year-long contracts running 24/7. So, each machine will generate on the order of $70,000 and $100,000 per annum. It costs us less than $60,000 to build the machine. So, the idea is to recover the cost of the machine in the first calendar years, and then the second, third, fourth, fifth year you are basically printing money.” Taking maintenance and service costs, cellular charges, and system upgrade costs into account, Santana estimates that each machine could generate up to $250,000 in profit over five years. The ADMs have numerous capabilities. They provide real-time access to data round the clock. For example, in a year, the machines generate over 90 terabytes of data that can be used for analysis purposes. And that’s not all. They also have features such as 360-degree eye-level HD video streaming, thermal anomaly detection, automatic license plate recognition (at a rate of 1,200 plates per minute), people detection, facial recognition (even for people wearing masks), and automatic signal detection. While the CEO’s utterances show promise and demonstrate Knightscope’s ideal prospects, the SEC filings tell a different story. Knightscope has been operating in the red. In the six months ending June 2019 and June 2020, the company reported net losses of $6.99 million and $9.14 million, respectively. Further, in the six months that followed, Knightscope posted $11.96 million and $13.39 million in net losses for the period ending December 2019 and December 2020, respectively. Knightscope CEO stated that the Company has built all of its technology from scratch and is now raising capital to scale the business to profitability. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Life sciences industry accelerator XPhyto Therapeutics Corp. has developed a timeline for the approval and rollout of a rapid, portable COVID-19 test it expects to become available by April in Europe
• XPhyto’s Covid-ID Lab system is designed to help industries economically devastated by the pandemic to form strategies based on quick and accurate testing, particularly the travel industry
• The company intends to use its test tech partnership with Germany’s 3a-diagnostics GmbH to build additional bacteriological and viral testing products
• A separate subsidiary based in Alberta is developing psychedelic medicine programs
• The subsidiary recently announced it has added mescaline production to the program for potential use in treating addiction and depression

Canada-based bioscience accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has completed all the preparatory actions necessary for it to apply for approval of its COVID-19 rapid and portable test system under European regulatory authorities, the company announced Feb. 16. The quick-response point-of-care SARS-CoV-2 RT-PCR Test System known as “Covid-ID Lab” developed in partnership with Germany’s 3a-diagnostics GmbH is designed to provide robust and accurate COVID-19 testing for economically devastated market sectors, with particular emphasis on travel industries. The announcement is one of a pair of company developments to emerge this month, including the expansion of the holding company’s psychedelic medicine programs. In regard to the COVID test, 3a expects to obtain approval as a medical device manufacturer under internationally agreed-on ISO 13485 quality standards by late February, followed by European regulatory approval of Covid-ID Lab as a commercial in vitro diagnostic device (CE-IVD) by early March, according to the company’s announcement (https://ibn.fm/89jKh). The companies then plan for manufacturing to begin in Germany with an April target for Covid-ID Lab’s sales launch in Europe. XPhyto is building relationships with partners in other countries to further advance the system’s sales and distribution. “Our goal was to create the fastest and most portable COVID-19 PCR test on the market,” XPhyto CEO and Director Hugh Rogers stated. “We are very pleased with the team’s swift development progress.” The pandemic has had a calamitous effect on the tourism industry during the past year, especially for popular island destinations ranging from Hawaii to Australia and New Zealand. Domestically, Hawaii has experimented with resort “bubbles” and recently announced a test-dependent Health Pass agreement that will help travelers avoid a mandatory 10-day quarantine once they arrive on the islands (https://ibn.fm/yuQQd), while United Airlines became the first U.S. carrier to establish an in-airport testing partner and information service, according to a CBS News report (https://ibn.fm/Af5A6). But the growing spread of COVID virus variants from the United Kingdom, South Africa and Brazil is creating new urgency about safeguarding international travel. India’s new air travel guidelines issued Feb. 18 are just the latest efforts to limit transmission of the worldwide health crisis, and experts believe varied restrictions will remain in place for a long time to come. “Like 9/11 changed air security forever, we’re still taking our shoes off,” XpresCheck CEO Doug Satzman stated in the CBS News report. “COVID is going to change safety protocol in airports for a long time as well.” The U.S. Centers for Disease Control and Prevention (“CDC”) has advised against such travel entirely, but has added testing recommendations for people who ignore its advice. In late January, the agency broadened international travel requirements, making negative COVID tests mandatory for passengers coming from any international location to the United States despite airline industry resistance (https://ibn.fm/rnoG3). XPhyto’s rapid-response test system aims to give businesses and government authorities a powerful tool in their arsenals, and the COVID response is only the beginning. The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, and is focusing on other potential pandemic biosensor tech efforts to combat the spread of the H1N1 (swine flu) and H5N1 (avian flu) viruses. The company states it is planning to launch its first biosensor product commercially during the latter half of 2021. Elsewhere, one of XPhyto’s holdings in Canada, XPhyto Laboratories Inc., has added mescaline production to its psychedelic medicine programs, according to a Feb. 3 announcement (https://ibn.fm/zyiEL). Mescaline is listed as a Schedule I drug in the United States without legally recognized medicinal benefits and with a high risk of abuse, but the psychedelic substance occurs naturally in some types of cactus and has limited legal use in certain religious ceremonies registered by the Native American Church and in certain research efforts. However, its use is expanding internationally as a supplement to various types of meditation and psychedelic therapies, according to the company. “Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression,” XPhyto’s news release states. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• PULL recently received Company Code from Canada’s Natural and Non-prescription Health Products Directorate
• Code allows PULL to submit application to sell its first functional mushroom product
• Company intends to submit additional NPN applications during 2021 as part of larger strategy to develop portfolio of functional mushroom wellness products

Functional mushrooms, those that provide a health benefit beyond just nutrition, are growing in popularity worldwide amid an accelerating trend to fend off viruses with immune-boosting food and drinks. Looking to seize part of a global functional mushroom market forecast by Data Bridge Market Research to hit $555.9 billion by 2028, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is checking the boxes to soon commercialize its new line of products.

Pure Extracts, a diversified plant-based extraction company with reach into cannabis, hemp, functional mushrooms and the burgeoning psychedelics sector, recently received a Company Code from Canada’s Natural and Non-prescription Health Products Directorate (“NNHPD”), an important step in moving towards sales. The code allowed the Company to submit an application for a Class 1 Natural Product Number, or NPN for short, for its first functional mushroom product.

Products that receive an 8-digit NPN have been assessed by Health Canada and deemed to be safe, effective and of high quality under the recommended conditions of use. Once approved, the NPN is added to the Licensed Natural Health Products Database where information about the product is available for viewing. The database includes information on a variety of natural health products, such as vitamin supplements, herb and plant-based remedies, probiotics, traditional medicines and more.

Pure Extracts intends to submit additional NPN applications during 2021 as part of its strategy to develop a portfolio of functional mushroom wellness products to sell through Pure Mushrooms Corp., its new, 100%-owned, subsidiary. Pure Mushrooms will employ a direct-to-consumer model, selling its goods through an e-Commerce portal being designed while the licensing process is under way. The new products will be sold under the “Pure Mushrooms” moniker.

Initially, the Company will work with a co-packer to meet consumer demand for Pure Mushrooms products while it explores optimizing existing extraction equipment at its state-of-the-art processing facility outside of Whistler, British Columbia. Planning ahead, Pure Extracts, which holds a Standard Processing License from Health Canada allowing it to manufacture cannabis goods, had its purpose-built facility constructed to meet Good Manufacturing Practices standards of the European Union, aligning for future global distribution of products and formulations were allowed by law.

Pure Extracts CEO Ben Nikolaevsky commented that his team is excited about the milestones ahead to enter the functional mushroom wellness sector that is experiencing “tremendous growth and consumer awareness.” He added that the company expects sales of the new products to begin by the end of this quarter.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical Inc. announced that it has now raised $2.165 million of the recent its convertible note offering
• The closing of the latest funding tranche will support the company’s progress toward the commercialization of its revolutionary bladder cancer visualization technology once final FDA approval is granted
• With better viewing options, the technology is designed to make it easier for surgeons to detect the full parameters of bladder tumors and remove them more completely
• Bladder cancer is one of the most prevalent cancers in the United States, particularly in men
• The technological improvement of these surgical procedures can provide an attractive cost benefit outcome and improved peace of mind as the potential need for repeated tumor-resecting procedures is reduced

As Imagin Medical (CSE: IME) (OTCQB: IMEXF) announces the closing of the second tranche of a convertible note offering to investors, the company continues building momentum toward the anticipated commercialization of its revolutionary cancer visualization technology. Imagin’s proprietary i/Blue Imaging (TM) System is a means of improving cystoscopies through the simultaneous use of white and blue imaging protocols that allow surgeons to detect and resect bladder tumors with greater accuracy and ease than has been possible before. The second tranche closing, announced Feb. 18 (https://ibn.fm/8gVHc), brings the amount raised for Imagin’s convertible note up to $2.165 million. Principal of notes that will accrue 10 percent interest annually and mature 18 months after the date of issue unless they are repurchased, redeemed or converted before that time. Imagin is aiming to commercialize its i/Blue Imaging (TM) System once final U.S. Food and Drug Administration (“FDA”) approval has been granted, and then apply its experience with the system toward the manufacture and commercialization of similar technology for use in other types of surgical procedures, i.e. laparoscopic. The I/Blue System uses blue light with a contrast agent, Cysview(TM) that causes the tumor to fluoresce  agent and deliver real-time images of the bladder for resection. While the existing blue light system has required surgeons to switch back and forth between white and blue light images, Imagin’s IP simplifies the process and makes it more effective by showing the white and blue light images side-by-side on the same monitor, utilizing hardware that is compatible with almost any endoscope already in use by hospitals and surgical centers so that they don’t have to acquire entirely new systems. The company estimates that approximately 95 percent of today’s cystoscopies continue to be performed with white light simply because of the hardware costs and challenges of acquiring blue light capability. Photocure reported to the 21st Annual Meeting of the Society of Urologic Oncology in December that its latest investigation found Cysview didn’t significantly affect the cost of cystoscopies and helped surgeons find tumor recurrences that would otherwise have been missed (https://ibn.fm/t9SLP). A report by Urology Times found that the use of blue light cystoscopy (“BLC”) under the trade name Cysview in tandem with white light during initial transurethral resection of bladder tumors (“TURB”) “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone” and led to a lower overall burden for patients (https://ibn.fm/Cz8GX). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• PowerTap Hydrogen Fueling has signed a definitive agreement with the Andretti Group to create an optimized network by leveraging the latter’s operational expertise and global reach
• PowerTap plans to have 500 operational hydrogen filling stations deployed across the country by the end of 2025
• The existing business model’s deployment of hydrogen stations expedites rollout due to the existing fuel operations on each site
• The hydrogen fuel cell vehicle market worldwide was valued at $651.9 million in 2018 and is expected to grow to over $42 billion by 2026

Stemming from the announcement made by Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) on January 26, 2021, about the Definitive Agreement between investee PowerTap Hydrogen Fueling and the Andretti Group for the production and deployment of hydrogen fuel units across California, more details have been released regarding the agreed-on business model, as well as the agreement’s benefits for the parties involved (https://ibn.fm/WYoYt).

PowerTap is working to build and expand its hydrogen fueling station network, initially across North America, starting the second half of 2021. The platform is believed to be more cost-effective and expandable than other hydrogen filling station’s models. The significant advantage over these companies comes from PowerTap’s smaller physical footprint and capacity to produce hydrogen on-site. Other companies purchase hydrogen at high prices and store it.

To be eligible to host a hydrogen fueling station, a site needs to meet a series of requirements, including: to have an existing fuels retailer, a usable area of at least 1000 square feet, as well as access to utilities, including natural gas, electricity, and water.

The key points for the business model are:

• The retailer provides the land, with no leasing expenses required of PowerTap
• PowerTap, at their own expense, will install and maintain the modular hydrogen production and dispensing unit. These expenses also include branding costs and utilities.
• The retailer will market hydrogen fuel and generate profit the same way traditional fuel sales are conducted.

Under the agreement, participating retails have a number of advantages, including:

• A high-yield opportunity to create revenue out of the land that is not being used to full potential
• Retailers are eligible to receive a portion of the carbon credit revenue
• Minimal operating costs and high earnings as an additional means of profit
• New clientele group, generating additional purchases of other products or services
• The on-site production allows a competitive price (go-to-market) versus the delivered supply price

The advantages for PowerTap include:

• No land purchase or leasing expenses
• Co-development that provides access to prime and higher trafficked real estate
• A faster entitlement process due to the existing fuel operation
• Ability to leverage the Andretti Group’s established operations expertise and geographical reach for a more optimized network
• Ability to expedite rollout, with the deployment of over 500 PowerTap modular hydrogen production and dispensing units by the end of 2025

The PowerTap technology has already been deployed across multiple hydrogen fueling stations in both public and private enterprises. These can be found in California, Maryland, Massachusetts, and Texas. By the end of 2025, PowerTap plans to deploy over 500 stations at existing truck stops and gas stations across the country. At present, there are under 100 active hydrogen fueling stations operational and available to consumers.

The hydrogen fueling network plan enables PowerTap and by extension Clean Power Capital to access a fast-growing market rife with expansion opportunities. According to Allied Market Research, the global hydrogen fuel cell vehicle market, valued at $651.9 million in 2018, is expected to grow at a CAGR of 66.9% to 2026, reaching an estimated value of $42,038.9 million (https://ibn.fm/Rg9Te). The key factor influencing the push for hydrogen fuel vehicles is the surge in environmental concerns over traditional fossil fuels. Hydrogen fuel does not generate greenhouse gas (“GHG”) emissions during operation like diesel and gasoline-powered vehicles.

The United States is already engaging in the hydrogen economy and currently leads in the number of hydrogen cell vehicles globally. The government is investing hundreds of millions of dollars per year in the hydrogen fuel industry, helping potentially create approximately 3.4 million jobs within the next three decades (https://ibn.fm/qF0M4).

For more information, visit the company’s website at www.CleanPower.Capital.

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19
• Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders
• VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment of social anxiety disorder and other anxiety-related disorders

Anxiety induced by the COVID-19 pandemic during the last year has been linked with surging use of benzodiazepines or “benzos,” a drug class commonly prescribed to treat anxiety and other disorders – a trend with potential to create a new wave of misuse, overuse and addiction among users while leaving physicians concerned about long-term detrimental side effects (https://ibn.fm/FFhjW). As a proactive response to what many critics are calling a “benzo epidemic” (https://ibn.fm/777mk), VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company headquartered in South San Francisco, is currently committed to developing a new generation of medicines that go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. VistaGen’s CNS pipeline includes multiple innovative drug candidates for treatment of anxiety and depression disorders, each of which has demonstrated favorable safety results in all clinical studies to date and significant commercialization potential in multiple neuropsychiatric markets. Anxiety is on the rise, according to a recent poll by the American Psychiatric Association, revealing that up to 62% of respondents have serious concerns about the effects of COVID-19 on themselves or loved ones. Additionally, prescriptions for benzodiazepines spiked 34% during the early stages of the pandemic according to a study of over three million people, suggesting a link between the rise of anxiety and increased coverage of the COVID-19 issue in the media. The use of benzodiazepines to treat anxiety has grown steadily since their discovery in the 1950s. Commonly classified as “minor tranquilizers,” benzodiazepines are prescribed to treat anxiety, panic disorders and seizures by calming nerve impulses and creating a sense of relaxation and well-being. Unfortunately, however fast-acting and highly effective they may be, benzodiazepines are also extremely addictive, earning them a Schedule IV controlled substance classification by the Drug Enforcement Agency (“DEA”) due to their potential for abuse. In September 2020, the FDA’s Drug Safety Communication (“DSC”) noted that there were 92 million prescriptions of benzodiazepines in 2019 and also detailed safety concerns regarding the serious risks of abuse, addiction, physical dependence, and withdrawal reactions linked to long-term use of benzodiazepines. As a result, in the DSC, the FDA announced that it is requiring an updated Boxed Warning, the FDA’s most prominent type of safety warning, for all benzodiazepine medications (https://ibn.fm/08UKT). According to many medical practitioners, benzodiazepines have serious long-term consequences. Use of the drug has been associated with the development of an increased tolerance that requires higher amounts to achieve the same effect. Additional long-term consequences include addiction, future cognitive problems and incapacitating withdrawal symptoms. VistaGen is committed to developing therapies that go beyond the limits of the current standard of care. To advance on that goal, VistaGen is currently preparing to launch Phase 3 clinical development of its PH94B for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), the third most common mental illness among Americans.  PH94B is a first in class pherine nasal spray designed with potential to deliver the rapid-onset anti-anxiety effects of benzodiazepines, but without the side effects and safety concerns associated with their use.  VistaGen currently anticipates launching its U.S. Phase 3 development program for acute treatment of SAD during the second quarter of this year.  The Company is also planning to launch exploratory Phase 2 studies in 2021 focused on several additional anxiety-related disorders, including adjustment disorder, postpartum anxiety, and pre-procedural (pre-MRI) anxiety (https://ibn.fm/bVbBy). For more information, visit the company’s website at www.VistaGen.com. NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• The FireFly ESV is a highway-legal, application specific, essential services vehicle that is also all-electric with zero emissions
• The vehicle uses the safest lithium-ion battery technology with an expected lifespan of 10 years and a longer operating time per charge
• The 2021 FireFly ESV promises to be the best equipped ESV model yet

Boston-based ev Transportation Services (“evTS”), a specialty vehicle manufacturer providing all-electric lightweight commercial utility vehicles and fleet management solutions, is changing how essential services management and urban e-mobility markets are handled via its highly versatile flagship product, the Firefly ESV (essential services vehicle).

To promote the FireFly ESV, ev Transportation Services announced in January 2021 that legendary golfing pro Ernie Els of South Africa would be serving as the FireFly Global Brand Ambassador (https://ibn.fm/mix0o).

Els is a former number one golfer with 72 professional career victories, including four Major Championships and two World Golf Championships, is also well known for his groundbreaking charitable work and fundraising efforts. Under a multi-year contract, evTS will utilize the golf star’s name, endorsement, and likeness in connection with the advertisement, promotion, and sales of evTS vehicles.

A highway-legal, three-wheeled commercial utility vehicle designed with performance and versatility in mind, the FireFly can be equipped with a number of application specific accessory options, such as License Plate Recognition systems and traffic safety features like directional emergency light bars. The vehicle’s modular bed comes in many purpose-built variants configured to meet the customer’s specialized use requirements, including features such as:

• Basic flatbed
• Electronic lift dump
• Lockable storage with ladder racks
• Insulated food delivery
• Mission specific EMS inserts
• Van (package delivery) box
• Refuse collection tipper
• And many other requested configurations

As an all-electric vehicle, the FireFly ESV uses the safest lithium-ion battery technology currently available (LiFePO₄, Lithium Iron Phosphate). This chemistry provides superior acceleration, a lighter weight design, improved energy-efficiency, and is highly reliable. A proprietary battery management system maintains and monitors the battery, ensuring optimal performance, charging, and range, with an expected lifespan of up to 10 years.

Unlike other vehicles that have been manufactured in the same class, the FireFly’s 102 Volt, 63 HP rated power train, makes it 15% more powerful than the current competition. The Integrated Drive System(TM) features a variable-rate electronic drive technology that optimizes speed and range – up to 100 miles or more per charge, travelling at electronically governed speeds exceeding 50 mph.

With technology like the evTS Data Acquisition System (“eDAS”), and the evTSCONNECT vehicle management portal, fleet operators can collect various performance data and statistical information about their FireFly ESV fleet. They can also track the vehicle’s movement through GPS monitoring and monitor the state of the battery charge.

evTS Chairman and CEO David Solomont said, “It is an honor to be associated with a gentleman who is respected not only in South Africa but throughout the world for his competitive spirit, genuine personality, and extensive philanthropic work.” Els voiced appreciation for evTS’ products and services and the company’s focus and ambition in the specialty vehicle market. “We all know where the world is heading in terms of the switch to electric vehicles and we feel evTS has unique opportunities and competitive advantages in the commercial sector,” he added.

For more information, visit the company’s website at www.evTS.com.

NOTE TO INVESTORS: The latest news and updates relating to ev Transportation Services are available in the company’s newsroom at https://ibn.fm/EVTS

• Mohawk’s proprietary platform, AIMEE(R), can identify consumer-driven needs and help handle the entire go-to-market process, from determining demand and market opportunities to production under the Mohawk brand
• The company currently owns 12 brands in the e-commerce industry – 5 launched and 7 acquired
• 2020 saw $1 billion in fresh capital from firms looking to acquire Amazon marketplace seller assets
• Sellers on the Amazon marketplace sold a total of $200 billion worth of products in 2019

Yaniv Sarig, CEO of Mohawk Group Holdings (NASDAQ: MWK), didn’t start out as the entrepreneur he is today. Born in Israel and the son of an electronics engineer, Sarig spent part of his childhood living in Europe before moving back to Israel. Required to serve three years in the Israeli Army, he joined the IDF Special Forces. These three years are what he believes prepared him for entrepreneurship. In a podcast interview on Gamechangers LIVE, Sarig stated that it was the Special Forces that made him realize that he could do more (https://ibn.fm/IyZem). He said that what you think you can do is only a fraction of what you are capable of doing, and without setting the bar higher and higher, you will never know what you are capable of. Sarig also said that the largest obstacle entrepreneurs face today is the fear of failure. When there is fear of failure, there is loss of innovation. Nobody wants to share ideas for fear of them being turned down. As an entrepreneur, the only want to succeed and grow in the business is to embrace those failures and learn from them, he added. Sergio Tigera, the host of Gamechangers LIVE, asked Sarig when his game-changing moment was that made his entrepreneurial drive stronger. He told Tigera that he lost someone close to him, and when that happened, there was a realization that he owed it to them to “make the most of it.” Now, setting the bar higher, Sarig is the CEO of Mohawk. This tech-enabled consumer-centered products platform uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. Through its proprietary platform AIMEE(R) (AI Mohawk e-Commerce Engine), Mohawk can identify what consumers are searching for, determine what they want based on feedback about these products, create a targeted product for the consumers, and launch it under a Mohawk branded name. Mohawk is also noticing those businesses that already meet the consumer’s demand but cannot rise above their current positioning in the market.  In these instances, Mohawk will look at the product’s potential. If everything is in order, it will acquire those assets from the seller to market under the Mohawk name. When bringing a product to market, Mohawk’s goal is to go from targeting a market need to putting it in a consumer’s hand in as little time as possible. Most go-to-market processes are a process that takes 18 to 24 months. The Mohawk go-to-market business model reduces this down to just 6 to 8 months, Sarig explained. AIMEE(R) helps reduce a lot of the idea focus group research by leveraging real-time data-driven opportunities and trend tracking. Marketing time is also reduced due to the AIMEE(R) Trading Engine that provides data-driven automated marketing and product lifetime management. With the recent acquisition of Healing Solutions LLC through an asset-only agreement, Mohawk currently has 12 brands (5 launched, 7 acquired) in the e-commerce industry. All of these have been launched or acquired based on a consumer-centric need determined by the company. There are millions of brands available through Amazon that have acquisition potential. In 2020, there was nearly $1 billion in fresh capital committed to doing so by firms looking to acquire the brands. In 2019, sellers on the marketplace sold $200 billion worth of products, with statistics indicating that if the Amazon marketplace were a country, it would rank as the world’s 50th largest economy (https://ibn.fm/dl3IS). For more information, visit the company’s website at www.Mohawkgp.com. NOTE TO INVESTORS: The latest news and updates relating to MWK are available in the company’s newsroom at https://ibn.fm/MWK